$PAVM

PAVmed (PAVM) reported Q2 2026 GAAP net loss of $5.5M, non-GAAP adjusted loss of $1.7M, and revenue of $33K. Lucid Diagnostics revenue was $1.5M, driven by 2,770 EsoGuard tests. Cash balance was $3.8M. Veris Health aims for 1,000 patients in its registry. PortIO study showed 100% device patency, and FDA submission is targeted for early 2027. Octeris IRB approval is expected in October 2026. The company has $15M in senior secured notes maturing in 2029.

PAVmed reported Q2 2026 earnings call updates. Management said Veris is moving from pilot to full commercialization at Ohio State, with two-thirds of planned departments onboarded and a goal of 1,000 patient enrollments in year one. It plans early-2027 FDA 510(k) for Veris and a Q4 pre-submission for PortIO, citing first-in-human data.

PAVmed (PAVM) held its Q2 2026 earnings call. GAAP net loss was $5.5 million ($0.87/share) and non-GAAP adjusted loss was $1.7 million ($0.27/share). Revenue was $33,000, with pro forma income over $3 million. Cash was $3.8 million at June 30. Management discussed Veris, Lucid Diagnostics, and device regulatory timelines, including a targeted early-2027 510(k) submission for Veris.

PAVmed Inc. (PAVM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Luci

PAVmed Inc. (NASDAQ: PAVM) reported Q2 2026 results for the quarter ended June 30, 2026 and provided business updates across subsidiaries Lucid Diagnostics (NASDAQ: LUCD), Veris Health, and Octeris. Lucid recognized $1.5M EsoGuard revenue and processed 2,770 tests, and secured first lab benefit manager coverage. PAVmed cash was $3.8M; GAAP net loss was $5.5M ($0.87/share).

PAVmed Inc. (PAVM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001624326 0001624326 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report

PAVmed Inc. (PAVM) is projected to report a loss of 70 cents per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The article is very brief and provides no additional details.

PAVmed Inc. has registered 9,230,786 shares of common stock for resale by existing stockholders, including shares issued from the conversion of Series D preferred stock and shares issuable from related warrants. The company will not receive proceeds from these resales, but could receive up to $30 million if the warrants are exercised. This registration allows selling stockholders to sell shares on public markets, subject to various market conditions and limitations.

Scott V. Dols has reported a beneficial ownership of 346,155 shares, representing a 5.4% stake in PAVmed Inc. (NASDAQ: PAVM). This disclosure was made via a Schedule 13G SEC filing, based on 6,383,089 shares outstanding as of March 27, 2026. Dols holds sole voting and dispositive power over these shares, which include 230,770 shares held in a trust where he serves as trustee.

PAVmed Inc. (PAVM) released its 2025 Q4 earnings, reporting an EPS of -$1.05, beating estimates by $3.45. The company's revenue reached $52.00K, a 420.00% year-over-year increase, also surpassing expectations by $52.00K. The article highlights the earnings call presentation slides published by PAVmed Inc.